Women with osteoporosis have at least a 50% chance of reaching their target bone mineral density at 3 years if they have a ...

The FDA has approved the BLA for Ospomyv™ and Xbryk™, biosimilars to Prolia (denosumab) and Xgeva (denosumab), respectively.

Q4 2024 Earnings Call Transcript February 28, 2025 Amneal Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS ...

In this article, we explore how aging impacts the musculoskeletal system and share expert-backed prevention tips to help you ...

The FDA recently removed semaglutide from its drug shortage list, which has not been considered commercially available since ...

Osteoporosis, often called a silent disease, weakens bones and increases the risk of fractures, making it a leading cause of ...

In a Korean national study, osteoporotic fracture was associated with higher risks for graft failure and death among kidney transplant recipients. Bone fracture from osteoporosis in kidney transplant ...

Samsung Bioepis Co., Ltd. today announced that the European Commission (EC) has granted marketing authorization for OBODENCE™ (60mg pre-filled syringe) and XBRYK™ (120mg vial), denosumab biosimilars ...

Women's Health Therapeutics Market Rising Awareness and Government Initiatives Drive Growth AUSTIN, TX, UNITED STATES, February 28, 202 ...

The global osteoporosis drugs market was valued at approximately USD 8.93 billion in 2022 and is expected to grow at a healthy CAGR of more than 3.9% during the forecast period from 2023 to 2030.

biosimilar candidate of PROLIA/XGEVA (denosumab). The acquisition expands Organon’s dermatology capabilities with a nonbiologic, non-steroidal topical treatment in the U.S.BASEL, Switzerland and ...